GlaxoSmithKline plc 5.4% Potential Upside Indicated by Liberum Capital

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

GlaxoSmithKline plc with EPIC/TICKER (LON:GSK) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘HOLD’ today by analysts at Liberum Capital. GlaxoSmithKline plc are listed in the Health Care sector within UK Main Market. Liberum Capital have set their target price at 1930 GBX on its stock. This is indicating the analyst believes there is a potential upside of 5.4% from today’s opening price of 1831.8 GBX. Over the last 30 and 90 trading days the company share price has increased 16.8 points and increased 150 points respectively. The 1 year high share price is 1851.15 GBX while the 52 week low for the share price is 1429.8 GBX.

GlaxoSmithKline plc has a 50 day moving average of 1,775.99 GBX and a 200 Day Moving Average share price is recorded at 1,683.34. There are currently 4,989,596,281 shares in issue with the average daily volume traded being 8,788,911. Market capitalisation for LON:GSK is £91,778,635,210 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges.
    GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025.

      Search

      Search